Abstract
Cancer treatment can be improved by using tiny particles, called nanoparticles, to deliver drugs directly to cancer cells. To understand how these drug-loaded nanoparticles work in the body, researchers create mathematical models that predict their behavior. These models help us understand how different factors—like the size and makeup of nanoparticles, the characteristics of tumors, and the body’s own responses—affect the treatment’s success. However, current models sometimes make assumptions that may not match what happens in real-life scenarios, causing us to overestimate the treatment’s effectiveness. This research aims to refine these mathematical models by incorporating more realistic data and advanced artificial intelligence techniques. These improvements may lead to more accurate predictions and ultimately make nanoparticle-based cancer treatments more successful in clinical settings, benefiting patients and advancing the field of cancer therapy.
Mathematical models are crucial for predicting the behavior of drug conjugate nanoparticles and optimizing drug delivery systems in cancer therapy. These models simulate interactions among nanoparticle properties, tumor characteristics, and physiological conditions, including drug resistance and targeting specificity. However, they often rely on assumptions that may not accurately reflect in vivo conditions. In vitro studies, while useful, may not fully capture the complexities of the in vivo environment, leading to an overestimation of nanoparticle-based therapy effectiveness. Advancements in mathematical modeling, supported by preclinical data and artificial intelligence, are vital for refining nanoparticle-based therapies and improving their translation into effective clinical treatments.